Oncolytic virotherapy potentiates chemo-PD-1 immunotherapy by engaging chemo-resistant bystander CD8+ T cells - PubMed
8 hours ago
- #CD8+ T cells
- #Oncolytic virotherapy
- #Immunotherapy
- Oncolytic virotherapy (OV-BYTE) enhances chemo-PD-1 immunotherapy by targeting chemotherapy-resistant bystander CD8+ T cells (TBYS).
- Platinum-based chemotherapy kills tumor-specific CD8+ T cells (TTST) but spares quiescent TBYS cells in the tumor microenvironment.
- OV-BYTE combined with chemotherapy engages TBYS cells for tumor killing and restores TTST cell function.
- Triple therapy (OV-BYTE + chemo + PD-1 ICB) improves antitumor efficacy in murine and patient-derived colorectal cancer models.
- TBYS cells are identified as a key therapeutic target to overcome chemo-immunotherapy limitations.